These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29308279)

  • 21. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
    J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originator.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O
    Eur J Rheumatol; 2017 Dec; 4(4):288-290. PubMed ID: 29308287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
    Sfikakis PP
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.
    Kambayashi H; Omori T; Saito S; Murasugi S; Kashiwagi H; Ito A; Yonezawa M; Nakamura S; Tokushige K
    Intern Med; 2020; 59(19):2343-2351. PubMed ID: 32999263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.
    Zhang M; Liu J; Liu T; Han W; Bai X; Ruan G; Lv H; Shu H; Li Y; Li J; Tan B; Zheng W; Xu H; Zheng W; Yang H; Qian J
    J Gastroenterol Hepatol; 2022 Apr; 37(4):608-619. PubMed ID: 34894004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
    Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
    Uyaroglu OA; Erden A; Kilic L; Peynircioğlu B; Karadag O; Kalyoncu U
    Acta Clin Belg; 2019 Oct; 74(5):364-369. PubMed ID: 30220250
    [No Abstract]   [Full Text] [Related]  

  • 29. Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis.
    Escudero-Vilaplana V; Ramírez-Herraiz E; Trovato-López N; Alañón-Plaza E; Bellini MJ; Herranz-Alonso A; Bellón-Cano JM; Morell-Baladrón A; Sanjurjo-Sáez M
    J Pharm Pharm Sci; 2012; 15(3):355-60. PubMed ID: 22974785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of non-TNF biologics for the treatment of neuro-Behçet's disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab.
    Karabulut Y
    Eur J Rheumatol; 2021 Oct; 8(4):223-227. PubMed ID: 34554909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
    [No Abstract]   [Full Text] [Related]  

  • 33. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The T-SPOT.TB assay used for screening and monitoring of latent tuberculosis infection in patients with Behçet's disease pre- and post-anti-TNF treatment: A retrospective study.
    Shen Y; Ma HF; Luo D; Guan JL
    J Chin Med Assoc; 2019 May; 82(5):375-380. PubMed ID: 30896580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.
    Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Bitossi A; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2018 Oct; 37(10):2805-2809. PubMed ID: 29766375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience.
    Bolek EC; Sari A; Kilic L; Kalyoncu U; Kurne A; Oguz KK; Topcuoglu MA; Ertenli I; Karadag O
    Mult Scler Relat Disord; 2020 Feb; 38():101512. PubMed ID: 31733425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
    Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
    Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
    Zlatanović G; Jovanović S; Veselinović D; Zivković M
    Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.